Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scinopharm Taiwan's Revenue for the
three
months ended in Mar. 2026 was NT$660 Mil. Scinopharm Taiwan's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$557 Mil.
Hence, Scinopharm Taiwan's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.19.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Scinopharm Taiwan Receivables Turnover Related Terms
Scinopharm Taiwan Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Receivables Turnover of 1.19 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scinopharm Taiwan and its competitors. According to the industry distribution chart, Scinopharm Taiwan ranks #298 out of 950 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Scinopharm Taiwan's Receivables Turnover too high?
Scinopharm Taiwan's current Receivables Turnover is 1.19. The Drug Manufacturers industry median Receivables Turnover is 5.07. Scinopharm Taiwan's value of 1.19 is 76.5% below this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #298 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #298 out of 950 companies for Receivables Turnover. This puts Scinopharm Taiwan in the upper half of its industry. The industry median Receivables Turnover is 5.07. Scinopharm Taiwan's value of 1.19 is 76.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Receivables Turnover of 1.19 is 76.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Receivables Turnover is 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$24.95, compared to a current price of NT$19.25 — trading 22.8% below its estimated fair value. The current Receivables Turnover is 1.19 and 76.5% below the Drug Manufacturers industry median of 5.07. Scinopharm Taiwan's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Receivables Turnover is 1.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.25 is trading 22.8% below its estimated GF Value™ of NT$24.95.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Receivables Turnover: 1.19
GF Value™: NT$24.95 vs. price of NT$19.25 (22.8% below fair value)
Industry Position: 76.5% below the Drug Manufacturers median (#298 of 950)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
70GF Score
Get the complete analysis for TPE:1789
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
